180 related articles for article (PubMed ID: 25791770)
41. [Blistering autoimmune dermatoses (II): therapy].
Goebeler M; Sitaru C; Zillikens D
J Dtsch Dermatol Ges; 2004 Sep; 2(9):774-91; quiz 792-3. PubMed ID: 16279223
[No Abstract] [Full Text] [Related]
42. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
[TBL] [Abstract][Full Text] [Related]
43. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
44. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
45. The safety of rituximab for the treatment of autoimmune blistering diseases: A systematic review.
Mohammed A; Hekman D; Li W; Misquith C; Rahnama-Moghadam S
J Am Acad Dermatol; 2022 Jun; 86(6):1439-1444. PubMed ID: 34214623
[No Abstract] [Full Text] [Related]
46. An overview of the diagnosis and management of immunoglobulin G4-related disease.
Haldar D; Cockwell P; Richter AG; Roberts KJ; Hirschfield GM
CMAJ; 2016 Sep; 188(13):953-961. PubMed ID: 27325130
[No Abstract] [Full Text] [Related]
47. Recent developments in steroid-responsive pancreatitides (autoimmune pancreatitis).
Sah RP; Chari ST
Curr Opin Gastroenterol; 2015 Sep; 31(5):387-94. PubMed ID: 26154429
[TBL] [Abstract][Full Text] [Related]
48. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
49. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
50. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
Rastetter W; Molina A; White CA
Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
[TBL] [Abstract][Full Text] [Related]
51. Drug insight: rituximab in renal disease and transplantation.
Salama AD; Pusey CD
Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
[TBL] [Abstract][Full Text] [Related]
52. Tolerability and safety of rituximab (MabThera).
Kimby E
Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
[TBL] [Abstract][Full Text] [Related]
53. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
[TBL] [Abstract][Full Text] [Related]
54. Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab.
Jensen AØ; Møller BK; Vangkilde A; Mark B; Obitz ER; Kragballe K; Iversen L
Br J Dermatol; 2009 Jun; 160(6):1359-61. PubMed ID: 19416252
[No Abstract] [Full Text] [Related]
55. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
56. Remission Time after Rituximab Treatment for Autoimmune Bullous Disease: A Proposed Update Definition.
Iranzo P; Pigem R; Giavedoni P; Alsina-Gibert M
Skin Pharmacol Physiol; 2015; 28(5):255-6. PubMed ID: 26021780
[TBL] [Abstract][Full Text] [Related]
57. Treatment of autoimmune blistering diseases.
Levy M; Rico MJ
Dermatol Clin; 1999 Apr; 17(2):431-40, x. PubMed ID: 10327307
[TBL] [Abstract][Full Text] [Related]
58. [An innovative approach to the treatment of immune-mediated glomerular diseases].
Roccatello D
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832439
[TBL] [Abstract][Full Text] [Related]
59. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
60. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
